Venous Thrombosis and Conjugated Equine Estrogen in Women Without a Uterus

Leiden University, Leyden, South Holland, Netherlands
Archives of Internal Medicine (Impact Factor: 17.33). 05/2006; 166(7):772-80. DOI: 10.1001/archinte.166.7.772
Source: PubMed


Postmenopausal hormone therapy has been associated with a 2- to 3-fold increased risk of venous thromboembolism (VT) (including deep vein thrombosis and pulmonary embolism) in observational studies and secondary prevention clinical trials. Clinical trial data on the effects of estrogen alone on VT are limited.
The Women's Health Initiative estrogen trial enrolled 10 739 women aged 50 to 79 years without a uterus. Participants were randomly assigned to receive conjugated equine estrogen (0.625 mg/d) or placebo.
During a mean of 7.1 years, VT occurred in 111 women randomly assigned to receive estrogen (3.0 per 1000 person-years) and 86 randomly assigned to receive placebo (2.2 per 1000 person-years; hazard ratio, 1.32; 95% confidence interval, 0.99-1.75). Deep venous thrombosis was reported in 85 women randomly assigned to receive estrogen (2.3 per 1000 person-years) and 59 randomly assigned to receive placebo (1.5 per 1000 person-years; hazard ratio, 1.47; 95% confidence interval, 1.06-2.06). The VT risk was highest in the first 2 years. There were no significant interactions between estrogen use and age, body mass index, or most other VT risk factors. Comparison of Women's Health Initiative VT findings for estrogen and previous Women's Health Initiative findings for estrogen plus progestin showed that the hazard ratios for estrogen plus progestin were significantly higher than those for estrogen alone (P = .03), even after adjusting for VT risk factors.
An early increased VT risk is associated with use of estrogen, especially within the first 2 years, but this risk increase is less than that for estrogen plus progestin.

Download full-text


Available from: Paul F Bray, Sep 02, 2014
  • Source
    • "Smoking itself is a weak risk factor for incident VT (Blondon et al, 2013). Therefore, our results suggest that smoking is not an important factor for the development VT in users of oral HT, similarly to those of the WHI clinical trial (Cushman et al, 2004; Curb et al, 2006). Our findings contrast with the observed synergistic effect of smoking and OC on the risk of VT (Pomp et al, 2008). "

    British Journal of Haematology 08/2013; 163(3). DOI:10.1111/bjh.12508 · 4.71 Impact Factor
  • Source
    • "Regarding pulmonary embolism, compared with those in the placebo group, women in the estrogen–progestin group experienced a statistically significant doubling of risk [15]. Assignment to estrogen alone appeared to raise the risk by 37%; this increase was not statistically significant [19]. No clear effect modification by age or time since menopause was apparent. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Menopausal estrogen therapy has a complex balance of benefits and risks and is no longer routinely recommended for the majority of women during or after the transition to menopause. Recent findings from the Women's Health Initiative (WHI) and other studies suggest that a woman's clinical and biological characteristics may modify her health outcomes on hormone therapy (HT) and that some women may be more appropriate candidates for therapy than others. An emerging body of evidence suggests that it may be possible to identify women who are more likely to have favorable outcomes and less likely to have adverse events on HT, as well as to tailor the optimal dose, formulation, and route of delivery of treatment, by the use of individual risk stratification and a personalized approach. Several clinical characteristics that have been proposed for this purpose include a woman's age, time since menopause, symptom severity, baseline vascular health, risk for breast cancer, biomarker levels, and genetic predisposition. The underlying rationale for personalized medicine, that each person has a unique biologic profile that can help to guide the choice of therapy, applies well to HT decision making and holds promise for improved treatment efficacy and safety. This report, which focuses on vascular health, reviews the evidence on the role of such markers in tailoring the use of hormone therapy to appropriate candidates, with the ultimate goal of developing a personalized risk:benefit prediction model that takes into account clinical and genetic factors, "patient-centered" outcomes including sense of well being and quality of life, and other variables. The proposed personalized approach to HT decision making has the potential to improve the quality of health care.
    Metabolism: clinical and experimental 09/2012; 62(1). DOI:10.1016/j.metabol.2012.08.015 · 3.89 Impact Factor
  • Source
    • "In some studies, the observed effects were similar for the two preparations for some outcomes , including stroke (Hendrix et al., 2006; Wassertheil- Smoller et al., 2003) and hip fracture (Cauley et al., 2003; Jackson et al., 2006), whereas E þ P effects were unfavorable compared to those for E-alone for other outcomes, including coronary heart disease (CHD) (Hsia et al., 2006; Manson et al., 2003), breast cancer (Chlebowski et al., 2003; Stefanick et al., 2006), and venous thromboembolism (VT) (Curb et al., 2006; Cushman et al., 2004). The spectrum of biological changes induced by hormone therapy in relation to the outcome effects has remained unclear. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Currently available technologies allow in-depth analysis of multiple facets of the proteome that have clinical relevance and that complement current genomics-based approaches. Although some progress has been made in our knowledge of the human proteome in health and in disease, there is an urgent need to chart a coherent road map with clearly defined milestones to guide proteomics efforts. Areas of emphasis include: (1) building resources, (2) filling gaps in our understanding of biological variation, and (3) systematically characterizing proteome alterations that occur in well-defined disease states, all of which require an organized and collaborative effort.
    Omics: a journal of integrative biology 03/2011; 15(3):133-9. DOI:10.1089/omi.2010.0111 · 2.36 Impact Factor
Show more